1-1 of 1
Authors: Jeffrey A Towbin
Journal Article
LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG) Open Access
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Page i92, https://doi.org/10.1093/neuonc/noac079.336
Published: 03 June 2022
